Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that MPI Research, a contract research organization (CRO) based in Mattawan Michigan, has implemented a Gyrolab xP workstation into their time-critical project workflows.
Alan Breau, Vice President for Bioanalytical/Analytical Services said, “Data from immunoassays underpin many critical decisions within complex project workflows. Our goal as a CRO is to deliver high quality results as rapidly and cost-effectively as possible to our clients in the biopharmaceutical industry. The automated, precise nanoliter-scale immunoassay platform from Gyros enables us to quickly develop project specific biomarker, pharmacokinetic (PK) and immunogenicity assays and to easily transfer the running of established assays thereby freeing staff for other tasks. The ability to work with such small volumes ensures that we maximize the number of assays that can be performed on samples that are often in limited supply. We believe that this investment will significantly impact the cost-efficiency as well as the turnaround time of our preclinical and clinical studies.”
Commenting on the announcement, Erik Walldén, CEO at Gyros, added: “With major biopharmaceutical companies using our platform to increase workflow efficiency, it is extremely pleasing that a growing number of their service providers are following suit. We have seen several examples of highly successful collaborations where both parties have benefited from increased productivity overall and noted the ease with which assays can be transferred between sites. This purchase by a well-established company such as MPI Research reflects the growing acceptance of our nanoliter-scale immunoassay platform within the industry.”
Date: April 26, 2011
Source: Gyros AB